In this episode of the Applied Clinical Trials Brief, we spotlight a recent video interview in which Jon Walsh, founder and ...

An overview of how recent funding reductions are reshaping clinical trial operations, from site sustainability and patient recruitment to trial design and long-term strategy.

In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), ...

With approval to proceed, the Phase II trial (NCT06092034) of RP-A501 for Danon disease restarts under an optimized dosing and immunomodulatory strategy.

Results from the Phase II OptiTROP-Lung01 trial (NCT05351788) showed that Sichuan Kelun-Biotech’s sac-TMT combined with ...

The first patient has been dosed in a global Phase II study assessing Hepzato in combination with trifluridine-tipiracil and bevacizumab for liver-dominant metastatic colorectal cancer, with primary ...

The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety ...

The FDA has awarded Breakthrough Therapy Designation to izalontamab brengitecan, a potential first-in-class bispecific ...

In this episode of the Applied Clinical Trials Brief, we recap our three most-viewed articles of the week—featuring updated ...

In this video interview, Caroline Potts, general manager of sites and patient services at Medical Research Network (MRN), explains why site-enabled approaches such as in-home visits and ...

Results from the Phase II COLLECTiVE202 trial (NCT05370885) demonstrated a statistically significant difference between VE202 ...

A 2025 survey highlights growing momentum for multi-indication drug development, with opportunities in innovative trial ...